Breaking Finance News

A statement released today by Stifel about Vernalis PLC (LON:VER) holds the target price at 99.00GBX

Stating a potential upside of 1.44%, Stifel hold steady the price target of Vernalis PLC (LON:VER) at 99.00GBX

On 09/22/2016, Panmure Gordon released a statement for Vernalis PLC (LON:VER) maintained the target price at 76.00GBX. At the time, this indicated a possible upside of 0.71%.

Boasting a price of 40.50GBX, Vernalis PLC (LON:VER) traded 3.70% higher on the day. With the last close down -8.10% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. The company has recorded a 50-day moving average of 43.63GBX and a two hundred day average of 45.70GBX. Volume of trade was down over the average, with 256,354 shares of VER changing hands under the typical 257,856

Performance Chart

Vernalis PLC (LON:VER)

Vernalis PLC has one year low of 31.00GBX and a one year high of 79.00GBX and has a total market value of 0 GBX.

In addition to Stifel reporting its target price, a total of 5 analysts have released a research note on the company. The average stock price target is 83.60GBX with 2 firms rating the stock a strong buy, 2 firms rating the stock a buy, one analyst rating the company a hold, zero equity analysts rating the company a underperform, and finally 0 firms rating the stock a sell.

General Information About Vernalis PLC (LON:VER)

Vernalis plc is a commercial-stage pharmaceutical holding company. The Company is engaged in the research, development and commercialization of pharmaceutical products for a range of medical disorders. The Company has two marketed products: Tuzistra XR in the United States prescription cough cold market, and frovatriptan, an acute treatment for migraine. The Company also has four prescription cough cold products under development, and a pipeline of research and new chemical entity (NCE) development programs. Its commercial pipeline candidates include CCP-05, CCP-06, CCP-07 and CCP-08. The Company operates in the United Kingdom, Rest of Europe, North America and Rest of the World. The Company is also engaged in fragment- and structure-based drug discovery. It has two development products in the central nervous system (CNS) therapeutic area: the fatty acid amide hydrolase (FAAH) inhibitor V158866 for pain, and V81444, an adenosine A2A receptor antagonist as a treatment for CNS diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.